NCT02560025View on ClinicalTrials.gov

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2018

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Alisertib

DRUG

Cytarabine

DRUG

Idarubicin

DRUG

Daunorubicin

Can be used in place of idarubicin

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Massachusetts General Hospital

OTHER